Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$61.17 USD
-0.15 (-0.24%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $61.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IONS 61.17 -0.15(-0.24%)
Will IONS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IONS
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
Other News for IONS
Is IONS ready to make a move? NR7 shows up after gaining 0.36%
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Eli Lilly & Co (LLY) and Revvity (RVTY)
Technical picture remains unchanged for IONS after it falls 3.23% on September 15
Insider Sell: Patrick O'Neil Sells 1,700 Shares of Ionis Pharmaceuticals Inc (IONS)
IONS falls 1.33% on September 12, leaving the technical picture intact